Loss of Cardiac PFKFB2 Drives Metabolic, Functional, and Electrophysiological Remodeling in the Heart
BACKGROUND: Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) is a critical glycolytic regulator responsible for upregulation of glycolysis in response to insulin and adrenergic signaling. PFKFB2, the cardiac isoform of PFK-2, is degraded in the heart in the absence of insulin signaling, contributing to diabetes-induced cardiac metabolic inflexibility. However, previous studies have not examined how the loss of PFKFB2 affects global cardiac metabolism and function.
METHODS AND RESULTS: To address this, we have generated a mouse model with a cardiomyocyte-specific knockout of PFKFB2 (cKO). Using 9-month-old cKO and control mice, we characterized the impacts of PFKFB2 on cardiac metabolism, function, and electrophysiology. cKO mice have a shortened life span of 9 months. Metabolically, cKO mice are characterized by increased glycolytic enzyme abundance and pyruvate dehydrogenase activity, as well as decreased mitochondrial abundance and beta oxidation, suggesting a shift toward glucose metabolism. This was supported by a decrease in the ratio of palmitoyl carnitine to pyruvate-dependent mitochondrial respiration in cKO relative to control animals. Metabolomic, proteomic, and Western blot data support the activation of ancillary glucose metabolism, including pentose phosphate and hexosamine biosynthesis pathways. Physiologically, cKO animals exhibited impaired systolic function and left ventricular dilation, represented by reduced fractional shortening and increased left ventricular internal diameter, respectively. This was accompanied by electrophysiological alterations including increased QT interval and other metrics of delayed ventricular conduction.
CONCLUSIONS: Loss of PFKFB2 results in metabolic remodeling marked by cardiac ancillary pathway activation. This could delineate an underpinning of pathologic changes to mechanical and electrical function in the heart.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of the American Heart Association - 13(2024), 7 vom: 02. Apr., Seite e033676 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harold, Kylene M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.1.105 |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 11.04.2024 published: Print-Electronic UpdateOf: bioRxiv. 2023 Nov 23;:. - PMID 38045353 Citation Status MEDLINE |
|---|
| doi: |
10.1161/JAHA.123.033676 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370234871 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370234871 | ||
| 003 | DE-627 | ||
| 005 | 20240412233140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/JAHA.123.033676 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370234871 | ||
| 035 | |a (NLM)38533937 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harold, Kylene M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of Cardiac PFKFB2 Drives Metabolic, Functional, and Electrophysiological Remodeling in the Heart |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Nov 23;:. - PMID 38045353 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) is a critical glycolytic regulator responsible for upregulation of glycolysis in response to insulin and adrenergic signaling. PFKFB2, the cardiac isoform of PFK-2, is degraded in the heart in the absence of insulin signaling, contributing to diabetes-induced cardiac metabolic inflexibility. However, previous studies have not examined how the loss of PFKFB2 affects global cardiac metabolism and function | ||
| 520 | |a METHODS AND RESULTS: To address this, we have generated a mouse model with a cardiomyocyte-specific knockout of PFKFB2 (cKO). Using 9-month-old cKO and control mice, we characterized the impacts of PFKFB2 on cardiac metabolism, function, and electrophysiology. cKO mice have a shortened life span of 9 months. Metabolically, cKO mice are characterized by increased glycolytic enzyme abundance and pyruvate dehydrogenase activity, as well as decreased mitochondrial abundance and beta oxidation, suggesting a shift toward glucose metabolism. This was supported by a decrease in the ratio of palmitoyl carnitine to pyruvate-dependent mitochondrial respiration in cKO relative to control animals. Metabolomic, proteomic, and Western blot data support the activation of ancillary glucose metabolism, including pentose phosphate and hexosamine biosynthesis pathways. Physiologically, cKO animals exhibited impaired systolic function and left ventricular dilation, represented by reduced fractional shortening and increased left ventricular internal diameter, respectively. This was accompanied by electrophysiological alterations including increased QT interval and other metrics of delayed ventricular conduction | ||
| 520 | |a CONCLUSIONS: Loss of PFKFB2 results in metabolic remodeling marked by cardiac ancillary pathway activation. This could delineate an underpinning of pathologic changes to mechanical and electrical function in the heart | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a echocardiography | |
| 650 | 4 | |a electrocardiography | |
| 650 | 4 | |a glucose | |
| 650 | 4 | |a glycolysis | |
| 650 | 4 | |a metabolism | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Phosphofructokinase-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.1.105 |2 NLM | |
| 650 | 7 | |a Pyruvates |2 NLM | |
| 650 | 7 | |a Pfkfb2 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.1.105 |2 NLM | |
| 700 | 1 | |a Matsuzaki, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Pranay, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Loveland, Brooke L |e verfasserin |4 aut | |
| 700 | 1 | |a Batushansky, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Mendez Garcia, Maria F |e verfasserin |4 aut | |
| 700 | 1 | |a Eyster, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Stavrakis, Stavros |e verfasserin |4 aut | |
| 700 | 1 | |a Chiao, Ying Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Kinter, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Kenneth M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Heart Association |d 2012 |g 13(2024), 7 vom: 02. Apr., Seite e033676 |w (DE-627)NLM222412712 |x 2047-9980 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:7 |g day:02 |g month:04 |g pages:e033676 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/JAHA.123.033676 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 7 |b 02 |c 04 |h e033676 | ||